Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-CD19/anti-CD20/anti-CD22 CAR T cells LCAR-AIO

A preparation of human T lymphocytes that have been genetically modified and transduced with a lentiviral vector expressing a chimeric antigen receptor (CAR) targeting the tumor-associated antigens (TAAs) cluster of differentiation 19 (CD19), CD20 and CD22, with potential immunostimulating and antineoplastic activities. Upon administration, the anti-CD19/anti-CD20/anti-CD22 CAR T cells LCAR-AIO target and bind to CD19, CD20 and CD22 expressed on the surface of certain tumor cells. This induces selective toxicity in tumor cells expressing these TAAs. The TAAs are overexpressed in certain hematologic malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-CD19/CD20/CD22 CAR T cells LCAR-AIO
tri-specific CD19xCD20xCD22 CAR T cells LCAR-AIO
Code name:LCAR-AIO
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search